Clinical Trials Logo

Healthy Subjects clinical trials

View clinical trials related to Healthy Subjects.

Filter by:

NCT ID: NCT06012578 Recruiting - Healthy Subjects Clinical Trials

Study Evaluating ISM5411 Administered Orally to Healthy Volunteers

Start date: November 8, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to learn about ISM5411 in healthy subjects. The primary objective is to evaluate the safety and tolerability of single and multiple oral doses of ISM5411 in healthy subjects.

NCT ID: NCT06011317 Recruiting - Healthy Subjects Clinical Trials

A Study of EDG-7500 in Healthy Adults

Start date: August 14, 2023
Phase: Phase 1
Study type: Interventional

The purposes of this Phase 1 study of EDG-7500 are to: 1. Learn about the safety of EDG-7500 after a single and multiple doses in healthy adults 2. Learn about how EDG-7500 is tolerated after a single and multiples doses in healthy adults 3. Evaluate the amount of EDG-7500 is in the blood and urine after single and multiple doses in healthy adults 4. Evaluate the effect of a meal on the amount of EDG-7500 that is in the blood in healthy adults 5. Evaluate whether the amount of EDG-7500 in the blood is similar for the suspension and tablet forms of EDG-7500 in healthy adults Participants will receive a single or multiple doses of EDG-7500 or a placebo by mouth.

NCT ID: NCT05951036 Recruiting - Healthy Subjects Clinical Trials

Effect of Blood Flow Restriction Training to Muscle Strength, Dynamic Stability, and ACL Injury Prevention

Start date: July 17, 2023
Phase: N/A
Study type: Interventional

The goal of this randomized clinical trial study is to compare low-load blood flow restriction (LL-BFRt), sham LL-BFRt, and high-load eccentric training (HL-Et) in healthy level 1 sportsman. The main questions it aims to answer are: 1. Does LL-BFR improve muscle strength better than sham LL-BFRt and HL-Et? 2. Does LL-BFR improve dynamic stability better than sham LL-BFRt and HL-Et? 3. Does LL-BFR prevent ACL injury better than sham LL-BFRt and HL-Et? Participants will be randomized into three intervention groups: LL-BFRt, sham LL-BFRt, and HL-Et. Participants will be asked to do: - In LL-BFRt, participants will be asked to do LL eccentric training (including double leg squats, split squats, deadlifts, and monster walks) with a 30% of repetition maximum (RM) and 70% of arterial occlusion pressure (AOP). - In sham LL-BFRt, participants will be asked to do LL eccentric training with a 30% of repetition maximum (RM) and 10% of arterial occlusion pressure (AOP). - In HL-Et, participants will be asked to do LL eccentric training with a 70% of repetition maximum (RM). Researchers will compare LL-BFRt, sham LL-BFRt, and HL-Et to see if muscle strength, dynamic stability, and ACL injury prevention improve after the interventions and follow-up.

NCT ID: NCT05843708 Recruiting - Healthy Subjects Clinical Trials

A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects

Start date: April 14, 2023
Phase: Phase 1
Study type: Interventional

The objectives of this study are: - To evaluate the effect of a low-fat meal on the pharmacokinetics (PK) of vorasidenib following a single oral dose of 40 mg vorasidenib in healthy adult subjects (substudy A) - To evaluate the effect of multiple-dose ciprofloxacin (strong cytochrome P450 [CYP]1A2 inhibitor) on the single-dose PK of vorasidenib in healthy adult subjects (substudy B)

NCT ID: NCT05822544 Recruiting - Obesity Clinical Trials

Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity

Start date: April 22, 2023
Phase: Phase 1
Study type: Interventional

The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects. The phase 1b portion of the study is designed to assess the safety, tolerability, and PK of TLC-6740 in subjects with obesity.

NCT ID: NCT05805033 Recruiting - Healthy Subjects Clinical Trials

Peri-Implant Soft Tissue Integration in Humans: Influence of Material

Start date: September 22, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the mucointegration of 2 types of surface roughness of zirconia abutments with titanium. The surface roughness will be machined and ultra-polished.

NCT ID: NCT05802810 Recruiting - Healthy Subjects Clinical Trials

The Mass Balance Study of [14C]JT001

Start date: March 18, 2023
Phase: Phase 1
Study type: Interventional

This study is a single center, single dose, non-randomized, open design clinical study.By quantitative analysis of the biological samples of subjects after oral administration of [14C]JT001, the data of human radioactive excretion rate and the main excretion pathway will be obtained. The main metabolites ,metabolic pathways and elimination pathways of JT001 will be identified.

NCT ID: NCT05685108 Recruiting - Healthy Subjects Clinical Trials

Optimizing Ultrasound-induced Anti-inflammation in Human Subjects

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

This is a feasibility study to determine whether pulsed ultrasound stimulation targeting the splenic nerve or the cervical vagus nerve can elicit an anti-inflammatory immune response in healthy volunteers.

NCT ID: NCT05651074 Recruiting - Healthy Subjects Clinical Trials

Assessment of the Effect of Omeprazole on Vicagrel in Healthy Subjects

Start date: November 14, 2022
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the effects of omeprazole on the PK and PD of a single dose of vicagrel in healthy subjects.

NCT ID: NCT05617183 Recruiting - Healthy Subjects Clinical Trials

Compare the Auto-injector and Pre-filled Syringe of CT-P47 in Healthy Subjects

Start date: November 15, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1 study to compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled syringe of CT-P47 in Healthy Subjects.